• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[贝伐单抗联合铂类化疗作为非小细胞肺癌六线治疗方案的1例报道]

[Bevacizumab with platinum chemotherapy as 6th-line treatment in a case of non-small-cell lung cancer].

作者信息

Ishiura Yoshihisa, Yamamoto Hiroki, Terasaki Yasushi, Ishida Youichi, Tohge Masayoshi, Segawa Masataka, Kusajima Yoshinori, Saitoh Katsuhiko, Ishikawa Mika, Hirokami Norikazu, Kasahara Kazuo, Fujimura Masaki

机构信息

Dept. of Medical Oncology, Toyama City Hospital.

出版信息

Gan To Kagaku Ryoho. 2011 Dec;38(13):2631-3.

PMID:22189231
Abstract

A 64-year-old man was admitted to our hospital for 6th-line chemotherapy. Chest X-ray film and computed tomographic (CT) scan showed right-sided pleural thickening with multiple lung tumors. Repeated treatment with carboplatin (AUC 6), paclitaxel (200 mg/m(2)) and bevacizumab (150 mg/kg) on day 1 every 21 days was effective for this patient. Chemotherapy with bevacizumab may be effective for patients with multi-recurrent adenocarcinoma.

摘要

一名64岁男性因接受第六线化疗入院。胸部X光片和计算机断层扫描(CT)显示右侧胸膜增厚并伴有多个肺部肿瘤。每21天在第1天重复使用卡铂(AUC 6)、紫杉醇(200 mg/m²)和贝伐单抗(150 mg/kg)进行治疗,对该患者有效。贝伐单抗化疗可能对多复发腺癌患者有效。

相似文献

1
[Bevacizumab with platinum chemotherapy as 6th-line treatment in a case of non-small-cell lung cancer].[贝伐单抗联合铂类化疗作为非小细胞肺癌六线治疗方案的1例报道]
Gan To Kagaku Ryoho. 2011 Dec;38(13):2631-3.
2
[A case of lung cancer showing marked reduction of pleural effusion by bevacizumab in combination with carboplatin and paclitaxel].1例肺癌患者使用贝伐单抗联合卡铂和紫杉醇后胸腔积液显著减少
Gan To Kagaku Ryoho. 2011 Nov;38(11):1877-9.
3
[Nab-Paclitaxel with platinum chemotherapy as sixth-line therapy for a non-small cell lung cancer patient].[纳米白蛋白结合型紫杉醇联合铂类化疗作为一名非小细胞肺癌患者的六线治疗方案]
Gan To Kagaku Ryoho. 2015 Apr;42(4):493-5.
4
[A case of complete resection of non-squamous non-small-cell lung cancer after induction chemotherapy using carboplatin, paclitaxel, and bevacizumab].[1例经卡铂、紫杉醇和贝伐单抗诱导化疗后非鳞状非小细胞肺癌完全切除的病例]
Gan To Kagaku Ryoho. 2012 Oct;39(10):1533-7.
5
Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancer.在未经治疗的晚期非小细胞肺癌患者中,比较伊沙匹隆联合卡铂与顺铂联合卡铂加或不加贝伐珠单抗的 II 期临床试验。
Lung Cancer. 2012 Oct;78(1):70-5. doi: 10.1016/j.lungcan.2012.06.008. Epub 2012 Sep 1.
6
[Efficacy of chemotherapy with carboplatin-paclitaxel plus bevacizumab for previously treated patients with advanced non-small cell carcinoma].卡铂-紫杉醇联合贝伐单抗化疗对既往接受过治疗的晚期非小细胞癌患者的疗效
Gan To Kagaku Ryoho. 2012 Dec;39(13):2509-12.
7
FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.美国食品药品监督管理局药物批准摘要:贝伐单抗(阿瓦斯汀)联合卡铂和紫杉醇作为晚期/转移性复发性非鳞状非小细胞肺癌的一线治疗方案
Oncologist. 2007 Jun;12(6):713-8. doi: 10.1634/theoncologist.12-6-713.
8
An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer.贝伐珠单抗联合卡铂和紫杉醇与培美曲塞联合顺铂治疗晚期或复发性非鳞状非小细胞肺癌的疗效间接比较。
Curr Med Res Opin. 2011 Nov;27(11):2193-201. doi: 10.1185/03007995.2011.626019. Epub 2011 Oct 4.
9
Treatment rationale and study design for a randomized trial of pemetrexed/carboplatin followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with advanced non-small-cell lung cancer of nonsquamous histology.培美曲塞/卡铂序贯培美曲塞维持治疗对比紫杉醇/卡铂/贝伐珠单抗序贯贝伐珠单抗维持治疗晚期非鳞状组织学类型非小细胞肺癌的随机临床试验:治疗原理和研究设计。
Clin Lung Cancer. 2010 Sep 1;11(5):352-7. doi: 10.3816/CLC.2010.n.045.
10
Induction pemetrexed and cisplatin followed by maintenance pemetrexed versus carboplatin plus paclitaxel plus bevacizumab followed by maintenance bevacizumab: a quality of life-oriented randomized phase III study in patients with advanced non-squamous non-small-cell lung cancer (ERACLE).培美曲塞和顺铂诱导治疗联合培美曲塞维持治疗对比卡铂+紫杉醇+贝伐珠单抗诱导治疗联合贝伐珠单抗维持治疗:晚期非鳞状非小细胞肺癌(ERACLE)患者的一项以生活质量为导向的随机 III 期研究。
Clin Lung Cancer. 2011 Nov;12(6):402-6. doi: 10.1016/j.cllc.2011.06.006. Epub 2011 Aug 10.